A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer-Reference-Cited by-同舟云学术

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer

Published:2012-05 Issue:5 Volume:23 Page:1164-1169
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Pallis A.G.,Boukovinas I.,Ardavanis A.,Varthalitis I.,Malamos N.,Georgoulias V.,Mavroudis D.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/5/1164/13785614/mdr405.pdf

Reference27 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. The global breast cancer burden: variations in epidemiology and survival;Hortobagyi;Clin Breast Cancer,2005

3. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer;Chia;Cancer,2007

4. Treatment of metastatic breast cancer: looking towards the future;Amar;Breast Cancer Res Treat,2009

5. First line chemotherapy of metastatic breast cancer;Pronzato;Ann Oncol,2006

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients;Cancer;2024-01-25

2. Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer;ESMO Open;2022-12

3. Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-Resistance;Clinical Breast Cancer;2022-10

4. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial;npj Breast Cancer;2022-09-20

5. Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials;Journal of Clinical Epidemiology;2022-07